Mylan and Forest Enter Agreement for Nebivolol
Posted on: Thursday, 12 January 2006, 15:01 CST
Mylan and Forest Laboratories have entered into an agreement for the development and distribution of Mylan's experimental blood pressure drug, nebivolol, in the US and Canada.
Under the terms of the agreement, Forest will make an upfront payment to Mylan of $75 million as well as potential future milestone payments. In addition, Mylan will also receive royalty payments based on nebivolol sales.
Forest will assume all nebivolol development expenses for current and future development programs as well as taking responsibility for all sales and marketing expenses. Mylan has retained an option to co-promote the product in the future.
Howard Solomon, chairman and CEO of Forest, said: "We are excited about the opportunity to market nebivolol, a highly beta-1 selective beta blocker which, based on the phase III studies included in the NDA filed by Mylan, appears to have favorable differentiating characteristics."
In May 2005 Mylan received an approvable letter from the FDA on its new drug application (NDA) for nebivolol for the treatment of hypertension. Final approval is contingent upon successfully satisfying additional FDA requirements included in the approvable letter. Mylan has completed a preclinical study designed to address certain questions posed by the FDA and is working towards submitting the results and other information to the FDA for their review.
In addition, Mylan intends to submit a separate nebivolol NDA to the FDA for the treatment of congestive heart failure. The submission, anticipated to occur sometime during the second half of calendar year 2006, will be based on data from a clinical study conducted in Europe by the Menarini Group.
Source: Datamonitor
Related Articles
- Reportlinker Adds Analysis of China's Future Development of Smart Grid, 2009
- A Report on R&D in Solar PV Technology - Understand Recent & Future Developments and the Place of Solar PV Technology in the Current Energy Market
- An Essential Study of Innovations and Pipelines for Respiratory Disorders: Discover Niche Markets, New Products and Future Developments
- Forecast Future Developments in the Traded Price of Gas and Power in Order to Successfully Take Advantage of Arbitrage Opportunities
- Finavera Renewables: AquaBuOY 2.0 Continues to Provide Key Data for Future Development of Commercial Wave Energy Converter
- RegeneRx Receives $545,000 Grant From FDA; Funding for Clinical Development of TB4 for Epidermolysis Bullosa
- Understand the Future Developments and Market Opportunities for the Molecular Diagnostics Market
- Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement
- Striving To Contain Costs Through Innovative Programs and Preventative Measures, Healthcare Professionals Manage the Present in Anticipation of Future Development - See Their Predictions for Healthcare Trends & Forecasts in 2006
- Future Developments in Transportation
 |
 |
User Comments (0)
RSS Feeds